Author: Li, Dongbo; Ji, Hongfei; Niu, Xingjian; Yin, Lei; Wang, Yiran; Gu, Yucui; Wang, Jinlu; Zhou, Xiaoping; Zhang, Han; Zhang, Qingyuan
Title: Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer Document date: 2019_12_19
ID: yj9mb88g_36
Snippet: Tumor-associated macrophages can adjust their phenotype and function in response to local cues provided by the TME. 49 Crosstalk between TAM and cancer cells is complex and involves exosomes, cytokines, and metabolites. [50] [51] [52] In the present study, we focused on the cytokine CCL2 secreted by macrophages and TA B L E 1 Univariate and multivariate analyses of clinicopathological features associated with PFS of patients with hormone receptor.....
Document: Tumor-associated macrophages can adjust their phenotype and function in response to local cues provided by the TME. 49 Crosstalk between TAM and cancer cells is complex and involves exosomes, cytokines, and metabolites. [50] [51] [52] In the present study, we focused on the cytokine CCL2 secreted by macrophages and TA B L E 1 Univariate and multivariate analyses of clinicopathological features associated with PFS of patients with hormone receptor-positive breast cancer examined its role in the endocrine resistance of breast cancer cells. We found that CCL2 activates the PI3K/Akt/mTOR pathway, which is a classical endocrine resistance pathway. However, the direct mechanism by which CCL2 activates this pathway was not determined. Another limitation of the present study was that due to the long culture time of drug-resistant cell lines, the effects of endocrine-resistant and -sensitive T47D cell lines on macrophages could not be repeated.
Search related documents:
Co phrase search for related documents- cell line and direct mechanism: 1, 2, 3
- cell line and drug resistant cell line: 1
- cell line and endocrine resistance: 1
- cell line and function phenotype: 1
- cell line and macrophage cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71
- cell line and pathway activate: 1, 2, 3
- cell line and present study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinicopathological feature and endocrine resistance: 1
- clinicopathological feature and endocrine resistance pathway: 1
- clinicopathological feature and hormone receptor positive breast cancer: 1
- clinicopathological feature and receptor positive breast cancer: 1
- culture time and pathway activate: 1
- culture time and present study: 1, 2, 3, 4, 5, 6, 7
- direct mechanism and present study: 1, 2
- endocrine resistance and hormone receptor positive breast cancer: 1
- endocrine resistance and pathway activate: 1
- endocrine resistance and present study: 1, 2, 3, 4
- endocrine resistance and receptor positive breast cancer: 1, 2
Co phrase search for related documents, hyperlinks ordered by date